期刊
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
卷 53, 期 10, 页码 1483-1493出版社
WALTER DE GRUYTER GMBH
DOI: 10.1515/cclm-2014-1048
关键词
Alzheimer; amyloid-beta; biomarkers; clinical chemistry; mass spectrometry; quantification
资金
- Programme hospitalier de recherche Clinique (PHRC)
- European FP7 Joint Programming on Neurodegenerative Diseases (JPND) BiomarkAPD
Alzheimer's disease (AD) is the most common form of dementia in humans, and a major public health concern with 35 million of patients worldwide. Cerebrospinal fluid (CSF) biomarkers being early diagnostic indicators of AD, it is essential to use the most efficient analytical methods to detect and quantify them accurately. These biomarkers, and more specifically amyloid-beta (A beta) peptides, are measured in routine clinical practice using immunoassays. However, there are several limits to this immunodetection in terms of specificity and multiplexing of the multiple isoforms of the A beta peptides. To overcome these issues, the quantification of these analytes by mass spectrometry (MS) represents an interesting alternative, and several assays have been described over the past years. This article reviews the different A beta peptides quantitative MS-based approaches published so far, compares their pre-analytical phase, and the different quantitative strategies implemented that might be suitable for clinical applications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据